[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Chiou et al., 2007 - Google Patents

Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation

Chiou et al., 2007

Document ID
3866081621953654625
Author
Chiou H
Li L
Hu T
Chan H
Chen J
Yun J
Publication year
Publication venue
International journal of pharmaceutics

External Links

Snippet

The purpose of this study was to produce salbutamol sulfate (SS) as a model anti-asthmatic drug using high-gravity controlled precipitation (HGCP) through antisolvent crystallisation. An aqueous solution of SS was passed through a HGCP reactor with isopropanol as …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Similar Documents

Publication Publication Date Title
Chiou et al. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation
Chan Dry powder aerosol drug delivery—Opportunities for colloid and surface scientists
Chew et al. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders
CA2890459C (en) Ultra low density pulmonary powders
JP4728558B2 (en) Method for producing nanoparticles
AU2002352836B2 (en) Improved particulate compositions for pulmonary delivery
EP2164622B1 (en) Surface modified aerosol particles, a method for production thereof and powders and dispersions containing said particles
Malamatari et al. Preparation of theophylline inhalable microcomposite particles by wet milling and spray drying: The influence of mannitol as a co-milling agent
CA2424620A1 (en) Inhalation particles incorporating a combination of two or more active ingredients
CN102149438A (en) Process for improving crystallinity
Chiou et al. A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation
Carr et al. Particle formation of budesonide from alcohol-modified subcritical water solutions
JP6449246B2 (en) Reduction of particle size of antimuscarinic compounds
Hu et al. Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation
Kramek-Romanowska et al. Effects of process variables on the properties of spray-dried mannitol and mannitol/disodium cromoglycate powders suitable for drug delivery by inhalation
CA2424621A1 (en) Combination particles for the treatment of asthma
CN108463213A (en) The preparation of inhalable zafirlukast particle
Shariare et al. Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronised salbutamol sulphate
EP1242048B2 (en) INHALATION PARTICLES: method of preparation
Muhammad et al. A novel method for the production of crystalline micronised particles
Muhammad et al. The production of dry powder by the sonocrystallisation for inhalation drug delivery
Xu et al. Preparation of high-performance ultrafine budesonide particles for pulmonary drug delivery
JP2008533055A (en) Inhalant
Muhammad et al. The effect of lactose micro-spherical crystals prepared by conditioning with supercritical fluid on salbutamol sulphate inhalation performance
Chen Engineering of Inhalation Aerosols Combining Theophylline and Budesonide